Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice

  1. Mansilla-Polo, M.
  2. Sahuquillo-Torralba, A.
  3. Pujol-Marco, C.
  4. Bargues-Navarro, G.
  5. Botella-Estrada, R.
Journal:
Anais Brasileiros de Dermatologia

ISSN: 1806-4841,  0365-0596

Year of publication: 2024

Type: Article

DOI: 10.1016/J.ABD.2024.04.004 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus